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Neurotoxic Methamphetamine 
Doses Increase LINE-1 Expression 
in the Neurogenic Zones of the 
Adult Rat Brain
Anna Moszczynska1, Amanda Flack1, Ping Qiu1, Alysson R. Muotri2 & Bryan A. Killinger1
Methamphetamine (METH) is a widely abused psychostimulant with the potential to cause 
neurotoxicity in the striatum and hippocampus. Several epigenetic changes have been described 
after administration of METH; however, there are no data regarding the effects of METH on the 
activity of transposable elements in the adult brain. The present study demonstrates that systemic 
administration of neurotoxic METH doses increases the activity of Long INterspersed Element 
(LINE-1) in two neurogenic niches in the adult rat brain in a promoter hypomethylation-independent 
manner. Our study also demonstrates that neurotoxic METH triggers persistent decreases in LINE-1 
expression and increases the LINE-1 levels within genomic DNA in the striatum and dentate gyrus of 
the hippocampus, and that METH triggers LINE-1 retrotransposition in vitro. We also present indirect 
evidence for the involvement of glutamate (GLU) in LINE-1 activation. The results suggest that 
LINE-1 activation might occur in neurogenic areas in human METH users and might contribute to 
METH abuse-induced hippocampus-dependent memory deficits and impaired performance on several 
cognitive tasks mediated by the striatum.
Methamphetamine (METH) is a potent and widely abused central nervous system (CNS) psychostim-
ulant that has been one of the major public health concerns worldwide since the late 1990s. METH 
abuse causes a broad range of severe cognitive deficits1 as well as neurobehavioral abnormalities, such as 
aggressive and psychotic behavior2, which are related to the neurotoxic effects of METH on the CNS. At 
high doses, METH causes the degeneration of dopaminergic (DAergic) and serotonergic nerve terminals, 
particularly in the striatum3. In neurons that are post-synaptic to striatal monoaminergic terminals, 
METH causes apoptosis, and cell death in some species4–8. In the hippocampus, METH dysregulates 
neurogenesis and induces apoptosis, which is often followed by the death of pyramidal neurons and 
granular cells8–14. Clinical studies in human METH users have found that the METH-induced long-term 
deficits in DAergic components in the striatum are correlated with cognitive decline and poor psycho-
motor functioning15, whereas the METH effects on the hippocampus play a role in long-term memory1.
Despite years of active research, there are no specific medications that can counteract the damaging 
effects of METH on adult brain. In recent years, epigenetics has attracted much attention as a novel 
and promising research area in METH abuse16. Most studies have investigated epigenetic changes in the 
nucleus accumbens that are induced by non-toxic doses of METH and have focused on histone mod-
ifications and global or gene-specific DNA methylation16–24. Several of these investigations examined 
amphetamine-induced epigenetic changes in the striatum17,18,20–22 and hippocampus19,23–25 using a variety 
of regimens and detected alterations in several epigenetic indices. Only a handful of studies employed 
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neurotoxic doses of acute or chronic METH and found that self-administration of high-dose METH 
triggered changes in histone modifications and the expression of genes coding for proteins involved in 
chromatin remodeling26,27, whereas neurotoxic binge METH decreased the expression of several histone 
deacetylases (HDACs)28 in the striatum. In the substantia nigra, high-dose METH injected over four days 
decreased DNA methylation within the promoter region of alpha-synuclein29.
Chromatin structure (via histone modifications), HDACs, and DNA methylation regulate transpos-
able elements (TEs)30–32, which are repetitive DNA sequences that can induce epigenetic alterations in 
the genome33,34. There are no data on the effects of METH on TEs in vivo. In neuronal cell lines, METH 
has been shown to trigger retrotransposition of Long INterspersed Element-1 (LINE-1)35. LINE-1 is 
the most abundant and the most active autonomous TE and is highly conserved in human and rodent 
DNA; it is dormant in most somatic cells and active during neurogenesis33,34,36. Dysregulation of LINE-1 
expression or retrotransposition contributes to several neurological diseases and can be triggered by 
substance abuse34. For example, LINE-1 expression in the nucleus accumbens increases after chronic 
administration of psychostimulant cocaine to mice30; the effect is accompanied by a decrease in trimeth-
ylated histone 3, a LINE-1-binding protein.
Based on the data from the literature and the fact that TEs do not undergo retrotransposition in 
non-proliferating cells, we hypothesized that neurotoxic binge METH would increase LINE-1 expression 
and the genomic DNA (gDNA) copy number in two neurogenic areas in the adult brain; the subgranular 
zone (SGZ) of the dentate gyrus and the subventricular zone (SVZ), which is located between the lateral 
ventricle and the striatum (Fig. 1A,B). The LINE-1 element consists of a promoter, 2 open reading frames 
(ORF-1 and ORF-2) and a polyA tail (Fig. 1C). LINE-1 activation, most often by promoter hypomethyla-
tion, leads to ORF-1 and ORF-2 translation in the cytoplasm, which can be followed by LINE-1 insertion 
Figure 1. A schematic illustration of the composition of the subgranular zone (SGZ), subventricular 
zone (SVZ) and Long INterspersed Element 1 (LINE-1). In the adult rodent brain, (A) the SGZ lies below 
the granular cell layer of the dentate gyrus whereas (B) the SVZ lies between the lateral ventricle and the 
striatum. These regions share several components such as astroglial neural stem cells (green), neuroblasts 
(orange) and progenitor cells (red). Black circles represent mature granular cells and striatal cells by the 
SGZ and SVZ, respectively; blue denotes an immature neuron in the SGZ (based on56). (C) The LINE-1 
element consists of the promoter-containing 5′ untranslated region (5′ UTR), 2 open reading frames (ORF-1 
and ORF-2), and a 3′ untranslated region (3′ UTR) with a polyA tail (based on34). Abbreviations: GCL, the 
granular cell layer; kbp, kilobase pairs; LV, the lateral ventricle; STR, the striatum.
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into the genome. To test our hypothesis in vivo, we measured LINE-1 promoter methylation, ORF-1 
messenger RNA (mRNA) levels, ORF-2 protein levels, and ORF-1 gDNA copy number in the rat brain. 
Cultured PC12 cells were used to elucidate the molecular mechanism mediating the increase in LINE-1 
expression. We present evidence that binge METH increases ORF-2 protein levels in the neurogenic 
zones as well as ORF-1 mRNA levels and ORF-1 copy number within gDNA in the rat dentate gyrus 
and striatum. We also provide in vitro data implicating METH-induced glutamate (GLU) toxicity in 
LINE-1 activation. These findings add to the knowledge of LINE-1 activity in neurons exposed to severe 
oxidative stress and suggest that activation of LINE-1 in vivo is a consequence of exposure to METH.
Results
Binge METH rapidly increases ORF-1 mRNA levels in the striatum and dentate gyrus of the 
adult rat brain. Severe hyperthermia during METH administration can serve as an indicator of the 
subsequent neurotoxicity of the drug; therefore, the core body temperature of each rat was recorded 
before, during, and after the administration of METH. As expected, METH triggered hyperthermia; i.e., 
METH administration caused significant increases in core body temperatures over time (p < 0.001, two-
way ANOVA with repeated measures followed by Student-Newman-Keuls post hoc test; n = 4–7 rats/
group) reaching 40°C after the last METH injection (Fig. 2A).
In the adult brain, LINE-1 retrotransposition occurs in neurogenic areas such as the SGZ, which lies 
within the dentate gyrus and the SVZ, which is adjacent to the lateral ventricle and striatum. Therefore, 
we first examined whether binge METH augments LINE-1 ORF-1 mRNA and ORF-2 protein levels 
in these neurogenic niches in the rat brain. METH significantly increased ORF-1 mRNA levels in the 
dentate gyrus and striatum at 24 h after the last injection of the drug (by 2.3-fold, p < 0.01, t = 3.69, 
df = 11, and 1.8-fold, t = 3.15, df = 8, p < 0.025, respectively; Student’s two-tailed t-test followed by the 
Bonferroni correction for multiple comparisons, n = 4–7 rats/group). This result suggests that binge 
METH augmented LINE-1 transcription in both regions at a point between the beginning of METH 
administration and 24 h after the last dose of the drug. Administration of cocaine, morphine or alcohol, 
increases LINE-1 expression in non-neurogenic brain areas34,37. Hence, we next assessed ORF-1 mRNA 
levels in Ammon’s horn of the hippocampus (CA1 and CA3), in the frontal cortex, and in the cerebellum. 
Rats were treated with METH or saline and were sacrificed 24 h after the last injection. METH did not 
affect the ORF-1 mRNA levels in any of these areas (p > 0.1, Student’s two-tailed t-test followed by the 
Bonferroni correction for multiple comparisons, 5 groups, n = 4–8 rats/group). The data are summarized 
in Fig. 2B.
There was no correlation between dentate gyrus or striatal ORF-1 mRNA levels and hyperthermia 
(ORF-1 mRNA levels vs. area under the temperature curve) (Pearson two-tailed correlation analysis, 
r = − 0.0051, p = 0.99 and r = − 0.279, p = 0.72, respectively), suggesting that the increase in ORF-1 mRNA 
levels was not caused by the increase in core body temperature.
Binge METH increases ORF-2 protein levels in neurogenic zones. LINE-1 is activated and read-
ily retrotransposes in proliferating cells. Consequently, we next examined rat brains for localization of 
ORF-2 protein immunoreactivity in the SGZ and the SVZ. Low ORF-2 protein immunoreactivity, con-
centrated in the perinuclear region, was detected in both the SGZ and SVZ zone in saline-treated rats 
(Fig. 3A, C). ORF-2 immunoreactivity was also detected in the striatum adjacent to the SVZ. At 24 h after 
the last injection, the METH-treated rats displayed higher ORF-2 protein immunoreactivity in the SGZ 
(by 2.1-fold, p < 0.005, Student’s two-tailed t-test with the Bonferroni correction, t = 6.30, df = 4) and in 
the adjacent granular cell layers than the saline-treated controls (Fig. 3B). A similar effect of METH was 
observed in the SVZ; binge METH-treated rats expressed more ORF2 protein in the SVZ than did the 
saline controls (by 3.1-fold, p < 0.025, Student’s two-tailed t-test with the Bonferroni correction, t = 4.21, 
df = 4) (Fig. 3C). In addition, an increased ORF-2 signal was observed outside the SVZ, in the portion 
of the striatum adjacent to the SVZ (Fig. 3D). Many, but not all, ORF-2-positive neurons were also pos-
itive for doublecortin, a selective marker of cells committed to the neuronal lineage, in both saline- and 
METH-treated rats.
Binge METH-triggered activation of LINE-1 is accompanied by low-level LINE-1 promoter 
hypomethylation in the dentate gyrus. LINE-1 activation is often induced by hypomethylation of 
its promoter region31,38. Examination of the first ten CpG sites within the promoter of LINE-1 revealed 
a small (− 1%) but significant (p < 0.025, Student’s one-tailed t-test with the Bonferroni correction 
for two comparisons (dentate gyrus, striatum), n = 5–7 rats/group) decrease in the average methyla-
tion of these sites in the dentate gyrus of binge METH-exposed rats relative to saline controls at the 
24 h time point (Table  1). As subsequently determined, the decrease was due to hypomethylation of 
CpG9 and CpG3 (− 3.5%, p < 0.0001, t = 7.84, df = 10 and − 1.9%, p < 0.005, t = 4.47, df = 10, respec-
tively, Student’s one-tailed t-test followed by the Bonferroni correction for multiple comparisons of 
CpGs, n = 5–7 rats/group) (Fig. 2C). Pearson’s correlation analysis did not reveal significant correlations 
between ORF-1 mRNA levels and the average methylation of CpGs 1–10 (Pearson’s r = 0.188, p = 0.685, 
n = 7 rats/group), or between ORF-1 mRNA levels and the methylation of CpG9 (Pearson’s r = 0.291, 
p = 0.526, n = 7 rats/group), or between ORF-1 mRNA levels and the methylation of CpG3 (Pearson’s 
r = 0.235 p = 0.511, n = 7 rats/group). In the striatum, no significant hypomethylation was detected in 
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METH-treated rats compared with the saline controls. Examination of LINE-1 promoter hypomethyl-
ation in the remaining hippocampus, frontal cortex, and cerebellum also did not reveal any significant 
changes. To determine whether LINE-1 promoter hypomethylation in the dentate gyrus and striatum 
occurred at an earlier time point than 24 h after the last METH dose, the rats were treated with binge 
METH or saline and sacrificed at 1 h after the last injection. No significant changes in LINE-1 promoter 
methylation were detected in the dentate gyrus or striatum (Table 2). These findings suggest that hypo-
methylation might not be a major factor in LINE-1 activation after the administration of binge METH.
Figure 2. METH-induced hyperthermia and short-term effects of binge METH on the levels of ORF-1 
mRNA in the rat brain. Adult male Sprague-Dawley rats were administered saline (1 mL/kg) or binge 
METH (4 × 10 mg/kg, i.p. every 2 h) and killed 24 h later. (A) METH-induced hyperthermia. Core body 
temperatures (°C) were measured before treatments and 1 h after each METH or saline injection. The black 
arrows indicate the injection times. Binge METH induced significant hyperthermia during the treatment 
(***p < 0.001, two-way ANOVA with repeated measures followed by the Student-Newman-Keuls post hoc 
test, n = 4–7/group). (B) Short-term effect of binge METH on the levels of ORF-1 mRNA in rat brain. 
Compared with the controls, METH significantly increased ORF-1 mRNA levels in the striatum (1.8-
fold, *p < 0.025) and the dentate gyrus (2.3-fold, **p < 0.01) (Student’s two-tailed t-test followed by the 
Bonferroni correction, n = 4–6 rats/group) at 24 h after METH administration. The data were normalized to 
the saline controls. (C) Short-term effect of binge METH on LINE-1 promoter methylation in the rat brain. 
The first ten CpG sites within the promoter region of LINE-1 were analyzed for methylation status (%). A 
small (− 1%) but significant (p < 0.05, Student’s two-tailed t-test, n = 5–7 rats/group) decrease in the average 
methylation of these sites was observed in the dentate gyrus of binge METH-exposed rats. The decrease was 
due to the hypomethylation of CpG9 and CpG3 (− 3.5%, ****p < 0.0001, and − 1.9%, *p < 0.005, respectively, 
Student’s two-tailed t-test followed by the Bonferroni correction for multiple comparisons, n = 5–7 rats/
group). The data are expressed as the mean ± SEM. Abbreviations: ave, average; CpG, cytosine guanine 
dinucleotide; h, hours; METH, methamphetamine; mRNA, messenger ribonucleic acid; SAL, saline.
www.nature.com/scientificreports/
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Figure 3. Short-term effects of binge METH on the levels of ORF-2 protein in the (A) subgranular 
zone (SGZ) of the dentate gyrus and (B) subventricular zone (SVZ). Adult male Sprague-Dawley rats 
were administered saline (1 mL/kg) or binge METH (4 × 10 mg/kg, i.p. every 2 h) and killed 24 h later. 
Representative images from 3 regions of the SGZ (A,B) and the SVZ (C,D) per condition (SAL vs. METH). 
METH-treated rats displayed higher ORF-2 protein immunoreactivity (green) in the SGZ (B vs. A) and 
SVZ (D vs. C) than the saline controls did (by 2.1-fold, *p < 0.0125, and 3.1-fold, **p < 0.005, respectively, 
Student’s two-tailed t-test with the Bonferroni correction). The data are summarized in (F). Low ORF-2 
protein immunoreactivity, concentrated in the perinuclear region, was detected in saline-treated rats in both 
zones (A,C). Many, but not all, ORF-2-positive neurons were also positive for doublecortin (arrows) (red), 
which is a selective marker of cells committed to the neuronal lineage, in both saline- and METH-treated 
rats. (E) Secondary antibody control. Nuclei are depicted in blue. Bars: (A-D) 50 μ m, (E) 25 μ m.
www.nature.com/scientificreports/
6Scientific RepoRts | 5:14356 | DOi: 10.1038/srep14356
Binge METH induces a persistent increase in the ORF-1 gDNA levels in the striatum and 
dentate gyrus of the adult rat brain. LINE-1 undergoes retrotransposition via a copy-and-paste 
mechanism and thereby increases its copy number within gDNA37. We next determined whether binge 
METH causes persistent increases in the levels of ORF-1 gDNA in the striatum and dentate gyrus. When 
the dentate gyrus and striatum were combined into one neurogenic group, the ORF-1gDNA levels were 
significantly increased (+ 71%, p < 0.01, Student’s two-tailed t-test, t = 13.7, df = 2, n = 8–11 rats/group) 
in METH-treated rats compared with the saline controls (Fig.  4A), suggesting potential LINE-1 retro-
transposition in the SGZ and SVZ. Examination of liver and muscle tissue revealed an increase in the 
levels of ORF-1 copy numbers in the liver (2.5-fold), but not in the muscle tissue, relative to the saline 
controls (Fig. 4C). Analysis of the data by Student’s t-test with the Bonferroni correction did not reveal 
significant differences between the saline and METH groups.
Binge METH regimen leads to a persistent decrease in ORF-1 mRNA levels in the dentate gyrus 
of the adult rat brain. Binge METH-induced neurotoxicity develops over 3–5 days3. To determine 
whether ORF-1 mRNA levels remain increased in the striatum and dentate gyrus after METH-induced 
Brain area CpG1 CpG2 CpG3 CpG4 CpG5 CpG6 CpG7 CpG8 CpG9 CpG10 Average
Striatum
SAL 84.5 ± 0.5 54.3 ± 0.3 73.6 ± 0.5 68.3 ± 0.7 77.8 ± 1.1 30.5 ± 0.1 99.7 ± 0.3 56.1 ± 0.7 65.7 ± 0.9 80.0 ± 0.3 69.0 ± 0.2
METH 85.3 ± 0.4 55.2 ± 0.3 74.0 ± 0.3 70.0 ± 0.8 77.4 ± 0.7 30.7 ± 0.3 100 ± 0 56.8 ± 0.7 65.7 ± 1.1 78.1 ± 0.4 69.3 ± 0.3
Dentate gyrus
SAL 84.5 ± 0.4 54.9 ± 0.4 74.6 ± 0.2 69.9 ± 0.6 76.2 ± 0.6 30.9 ± 0.4 99.7 ± 0.3 57.4 ± 0.6 66.4 ± 0.2 78.2 ± 0.6 69.3 ± 0.2
METH 85.6 ± 0.4 54.9 ± 0.5 72.7 ± 0.3# 68.5 ± 0.8 76.8 ± 1.0 30.2 ± 0.2 99.4 ± 0.6 55.9 ± 0.2 62.9 ± 0.4# 79.2 ± 0.4 68.5 ± 0.3*
Hippocampus
SAL 84.4 ± 0.2 54.5 ± 0.4 74.4 ± 0.2 70.1 ± 0.6 75.8 ± 0.8 30.9 ± 0.3 99.7 ± 0.2 57.5 ± 0.2 66.3 ± 1.0 80.1 ± 0.4 69.5 ± 0.1
METH 85.7 ± 0.4 54.8 ± 0.5 73.4 ± 0.4 69.5 ± 0.6 76.6 ± 0.6 30.6 ± 0.3 99.8 ± 0.2 56.0 ± 0.5 66.4 ± 0.4 78.4 ± 0.6 69.1 ± 0.2
Frontal cortex
SAL 83.9 ± 0.3 54.5 ± 0.3 73.3 ± 0.4 68.8 ± 0.6 77.1 ± 0.6 29.6 ± 0.2 100 ± 0 54.6 ± 0.4 64.2 ± 0.6 78.1 ± 0.4 68.4 ± 0.2
METH 84.9 ± 0.4 53.9 ± 0.3 72.8 ± 0.4 69.2 ± 0.3 75.8 ± 0.5 29.7 ± 0.3 99.8 ± 0.2 54.8 ± 0.5 65.0 ± 0.5 76.9 ± 0.6 68.3 ± 0.2
Cerebellum
SAL 86.0 ± 0.5 55.6 ± 0.3 74.8 ± 0.3 71.4 ± 0.8 77.0 ± 0.9 31.3 ± 0.3 100 ± 0 57.5 ± 0.3 66.5 ± 1.1 79.3 ± 0.7 69.9 ± 0.3
METH 86.5 ± 0.2 55.5 ± 0.4 75.9 ± 0.3 71.1 ± 0.3 77.0 ± 0.5 31.8 ± 0.3 99.9 ± 0.1 58.1 ± 0.5 67.4 ± 0.2 78.3 ± 0.3 70.1 ± 0.2
Table 1.  The effect of binge methamphetamine (METH) on methylation status of LINE-1 promoter 
in several areas of rat brain assessed at 24 h after binge METH or saline (SAL). Statistically significant: 
*p < 0.05 (Student’s t-test), #p < 0.005 (Student’s t-test with the Bonferroni correction), n = 5–7 rats/group. 
First ten C-phosphate-G (CpG) sites within the promoter region were assessed for percent of methylation 
by pyrosequencing in saline- and METH-treated rats at 24 h after the last injection of the drug or saline. 
Average methylation of LINE-1 promoter was significantly decreased in the dentate gyrus (− 1%) due to 
hypomethylation at the CpG3 and CpG9 site.
Brain area CpG1 CpG2 CpG3 CpG4 CpG5 CpG6 CpG7 CpG8 CpG9 CpG10 Average
Striatum
SAL 86.1 ± 0.3 57.3 ± 0.5 66.0 ± 0.3 81.2 ± 0.4 98.6 ± 0.4 33.9 ± 0.4 100 ± 0 59.2 ± 0.4 66.6 ± 0.5 80.6 ± 0.5 72.8 ± 0.3
METH 86.6 ± 0.2 57.7 ± 0.1 66.4 ± 0.3 79.5 ± 0.4 97.4 ± 1.2 33.4 ± 0.3 100 ± 0 60.1 ± 0.5 67.4 ± 0.7 79.2 ± 0.7 73.0 ± 0.2
Dentate gyrus
SAL 86.6 ± 0.3 57.1 ± 0.3 66.6 ± 0.8 80.3 ± 0.6 98.7 ± 0.9 32.6 ± 0.7 100 ± 0 58.5 ± 0.7 58.5 ± 0.7 66.2 ± 0.4 73.0 ± 0.2
METH 86.6 ± 0.2 58.0 ± 0.5 67.0 ± 0.8 81.0 ± 0.6 95.7 ± 0.6 34.5 ± 0.7 100 ± 0 60.2 ± 0.5 60.2 ± 0.5 67.2 ± 0.8 72.8 ± 0.4
Table 2.  The effect of binge methamphetamine (METH) on methylation status of LINE-1 promoter in 
the dentate gyrus and striatum assessed at 1 h after binge METH or saline (SAL). First ten C-phosphate-G 
(CpG) sites within the promoter region were assessed for percent of methylation by pyrosequencing in 
saline- and METH-treated rats at 1 h after the last injection of the drug or saline. Average methylation of 
LINE-1 promoter was not significantly changed either in the dentate gyrus or striatum.
www.nature.com/scientificreports/
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neurodegeneration has occurred, METH-treated and control adult rat brains were examined for the lev-
els of ORF-1 mRNA at 7 days after binge METH treatment. When the dentate gyrus and striatum were 
combined into one neurogenic group, ORF-1 mRNA levels were significantly decreased (− 49%, p < 0.05, 
Student’s two-tailed t-test, t = 6.1, df = 2, n = 5–7 rats/group) in METH-treated rats compared with the 
saline controls (Fig. 4B). As presented in Fig. 3D, the ORF-1 mRNA levels showed a significant decrease 
only in the liver when the data were analyzed with Student’s t-test with the Bonferroni correction (− 91%, 
p < 0.0125). The levels of ORF-1 mRNA in muscle tissue did not significantly differ between METH- and 
saline-treated rats (Fig.  4D). The results suggested that binge METH-induced LINE-1 activation was 
followed by an adaptive decrease in LINE-1 expression. Interestingly, the ORF-1 mRNA levels nega-
tively correlated with the ORF-1 gDNA levels in the dentate gyrus (r = − 0.744, p < 0.05, n = 6, Pearson’s 
analysis) but not in the striatum. The power of the analysis was π = 0.55; nevertheless, the correlation 
Figure 4. Long-term effect of binge METH on the levels of ORF-1 mRNA and gDNA in rat brain, 
liver and muscle. Adult male Sprague-Dawley rats were administered saline (1 mL/kg) or binge METH 
(4 × 10 mg/kg, i.p. every 2 h) and sacrificed 7 days after the treatment. Compared with the saline controls, 
METH significantly increased ORF-1 gDNA levels (A) and decreased ORF-1 mRNA levels (B) in the 
neurogenic regions of the brain (dentate gyrus and striatum combined) (+ 71%, **p < 0.01, n = 8–11 and 
− 49%, *p < 0.05, n = 5–7, respectively, Student’s two-tailed t-test). (C) When ORF-1 gDNA was assessed 
in the striatum, dentate gyrus, liver, and muscle, no significant changes were detected using the Student’s 
t-test with the Bonferroni correction. Data unadjusted for multiple comparisons revealed an increase in 
ORF-1 gRNA in the dentate gyrus and striatum and a statistical trend for an increase in the liver (+ 66%, 
p < 0.05, + 76%, p < 0.05 and 2.5-fold, p = 0.064, respectively, Student’s one-tailed t-test). (D) When 
ORF-1 mRNA was assessed in the striatum, dentate gyrus, liver, and muscle (using Student’s t-test with the 
Bonferroni correction), a significant decrease was observed only in the liver (− 91%, *p < 0.0125). Data 
unadjusted for multiple comparisons revealed a decrease in ORF-1 mRNA in the dentate gyrus and striatum 
(− 41%, p < 0.05 and − 57%, p < 0.05, respectively, Student’s one-tailed t-test). The data are expressed as 
the mean ± SEM. All data were normalized to the saline controls. Abbreviations: d, days; dg, dentate gyrus; 
gDNA, genomic deoxyribonucleic acid; METH, methamphetamine; mRNA, messenger ribonucleic acid; str, 
striatum; SAL, saline.
www.nature.com/scientificreports/
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suggests that the reduction in ORF-1 mRNA levels in the dentate gyrus might be partially due to LINE-1 
translocation from the cytoplasm to the nucleus.
METH triggers GLU-mediated LINE-1 retrotransposition in neuronal cells. Exposure of neu-
ronal DAergic PC12 cells to millimolar concentrations of METH in vitro triggers DA-mediated neuro-
toxic events, including apoptosis and oxidative DNA damage39. LINE-1 undergoes retrotransposition in 
PC12 cells after 3 days of exposure to 0.5 mM METH35. To test whether LINE-1 undergoes retrotrans-
position in PC12 cells and in PA-1 cells (which are non-neuronal) after METH treatment, the cells were 
exposed to 0.150 and/or 0.300 mM of the drug for 10–14 days after transfection with constructs contain-
ing a LINE-1 retrotransposition indicator cassette (LRE3-eGFP) or retrotransposition-defective LINE-1 
(containing two missense mutations in ORF1) (JM111-eGFP) as well as the puromycin resistance gene36. 
Cells harboring the constructs were selected by the addition of puromycin to the culture medium and 
screened for eGFP fluorescence. In PC12 cells, the GFP signal appeared, in a dose-dependent manner, 
after 10–14 days of METH treatment (Fig. 5A,a–c,f–h). Cells transfected with retrotransposition-defective 
LINE-1 did not show eGFP immunofluorescence (Fig. 5A,d-e,i–j). To determine whether METH is able 
to trigger LINE-1 retrotransposition in non-neuronal cells (specifically, ovarian cancer cells), PA-1 cells 
were exposed to 0.300 mM METH while PC12 cells were exposed to 0.150 mM METH. As previously, the 
incubation of PC12 cells harboring retrotransposition-capable LINE-1 with 0.150 mM METH triggered 
LINE-1 retrotransposition (Fig.  5B,a–b). Exposure of PC12 cells to METH and a LINE-1 retrotrans-
position inhibitor (azidothymidine, AZT) decreased the number of GFP-positive cells (Fig.  5B,c), thus 
confirming that LINE-1 retrotransposition was the source of the eGFP signal. Incubation of PA-1 cells 
with 0.300 mM METH also resulted in generation of eGFP fluorescence, but the signal was weaker than 
in PC12 cells (Fig. 5B,d-e). These findings indicate that METH can induce LINE-1 retrotransposition in 
neuronal and non-neuronal cells. The neurotoxic effects of METH on postsynaptic neurons are medi-
ated via increased neurotransmission of DA and GLU3. To determine whether DA and/or GLU mediate 
an increase in LINE-1 expression, PC12 cells were treated with 2 mM DA or 2 mM GLU for 4 h. Both 
neurotransmitters decreased cell viability as assessed with propidium iodide (Fig.  5C,a–c). Compared 
with untreated cells, GLU increased ORF-2 immunoreactivity more than DA did (Fig.  5c,e–i). ORF-2 
immunoreactivity was not detected in JM111-eGFP-transfected cells (not shown).
Discussion
The present study demonstrates that the systemic administration of binge METH, at neurotoxic doses, 
to adult male rats increases the ORF-1 mRNA and ORF-2 protein levels in the SGZ and SVZ at 24 h 
after the last dose of the drug, in a LINE-1 promoter hypomethylation-independent manner. Our study 
also demonstrates that binge METH triggers persistent (up to 7 days after METH regimen) decreases 
in ORF-1 mRNA levels and increases the levels of ORF-1 gDNA in the dentate gyrus and striatum. The 
in vitro component of the investigation presents evidence for METH-triggered LINE-1 retrotransposition 
in neuronal and non-neuronal cells and implicates the neurotransmitter GLU in the increases in LINE-1 
expression.
Binge METH significantly increased ORF-1 mRNA levels in the dentate gyrus and striatum at 24 h 
after binge METH administration. Increased LINE-1 expression at the 24 h time point has also been 
found in the mouse nucleus accumbens after exposure to another psychostimulant, cocaine30, and in 
cultured DAergic cells exposed to morphine40, as well as in several brain areas of alcoholics41, suggesting 
a common pathway of LINE-1 induction by these substances. The morphine-induced increase in LINE-1 
expression was found to be triggered by the inhibition of cysteine transport into SH-SY5Y cells and the 
consequent deficit in intracellular GSH40. GSH deficit can be generated by severe oxidative stress (medi-
ated by DA autoxidation or mitochondrial dysfunction) or by exposure to GLU, which inhibits cysteine 
transport42. In fact, binge METH induces oxidative stress, mitochondrial impairment, and a GSH deficit 
in the rodent striatum4-8,43,44 and hippocampus8,43,45–47, as well as triggers DA and GLU release in these 
areas48,49. Oxidative stress, mitochondrial impairment, and a GSH deficit have all been demonstrated 
to increase LINE-1 mRNA levels in culture50,51. METH, cocaine, morphine, and alcohol all can induce 
oxidative stress and a deficit in GSH40,44,52, suggesting that an imbalanced in redox status is a common 
final pathway leading to LINE-1 activation, with GLU release, rather than DA release, mediating the 
imbalance. The notion of GLU as major mediator of LINE-1 overproduction is supported by our finding 
of increased ORF-2 immunoreactivity in PC12 cells treated with GLU (but not in cells treated with DA) 
and by a report of attenuated METH-induced cell death in the dentate gyrus by the inhibition of GLU 
release46.
The investigation into sites of LINE-1 activation revealed significantly increased levels of ORF-2 pro-
tein in the SGZ and SVZ, indicating that METH induces LINE-1 translation mainly in neurogenic areas. 
Moreover, METH increased the levels of ORF-2 protein in the portion of the striatum adjacent to the 
SVZ, which might have been a result of local neurogenesis53, migration of precursor cells generated in 
the SVZ to the damaged striatum54, or increased LINE-1 expression in a sub-population of striatal cell 
bodies. ORF-2 immunostaining was present in both doublecortin-positive and doublecortin-negative 
cells, indicating increased LINE-1 activation in neuronal precursors differentiating into neurons (in 
agreement with the results of Muotri and colleagues36), as well in other cell types. In vitro, we detected 
METH-induced LINE-1 retrotransposition in neuronal PC12 cells, which agrees with a previous study35, 
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Figure 5. Effect of METH on LINE-1 retrotransposition in dopaminergic neuronal PC12 cells and 
non-dopaminergic non-neuronal PA-1 cells. Cells were transfected with either an active LINE-1 (LRE3-
eGFP) or retrotransposition-defective LINE-1 (JM111-eGFP). (A) In untreated PC12 cells, eGFP expression 
(green) was detected after 10–14 days in a very few cells (f). PC12 cells transfected with JM111-eGFP did 
not show eGFP immunofluorescence (i,j). Incubation of LRE3-eGFP-transfected PC12 cells with 0.150 mM 
or 0.300 mM METH for 10–14 days resulted in higher LINE-1 retrotransposition as manifested by stronger 
eGFP fluorescence (g,h). (B) Incubation of PA-1 cells with 0.300 mM METH also resulted in the appearance 
of an eGFP signal (white arrows) at a higher METH concentration; the eGFP signal was of lower intensity 
than the eGFP signal in PC12 cells (Be vs. Ah). Incubation of LRE3-eGFP-transfected PC12 cells with a 
LINE-1 retrotransposition inhibitor, azidothymidine (AZT), completely abolished the eGFP signal (c vs. a,b). 
No eGFP signal was detected in untreated PA-1 cells (d). (C) Administration of 2 mM glutamate (GLU) 
or dopamine (DA) for 4 h decreased PC12 cell viability as evidenced by increased propidium iodide (red) 
accumulation (a, no treatment; b, DA; c, GLU). Compared with untreated PC12 cells (Cg), the 2 mM GLU 
treatment induced a greater increase in ORF-2 immunoreactivity (green, red arrows) (Ce,f) than 2 mM DA 
treatment did (Ch,i). (Dg) Secondary antibody negative control. Inserts present magnifications of red arrow-
marked areas containing ORF-2 immunoreactivity. Abbreviations: eGFP, enhanced green fluorescent protein; 
METH, methamphetamine; SAL, saline. Bars: (A,Ca-c) 400 μ m, (B,Cd-i) 200 μ m.
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as well as in non-neuronal PA-1 cells, albeit to a lesser extent, which supports our in vivo findings of 
increased LINE-1 activity in doublecortin-negative cells. In terms of the involvement of GLU in mediat-
ing the increases in LINE-1 expression, METH may increase extracellular GLU levels within neurogenic 
areas via DA release from DAergic terminals followed by GLU release from astrocytes55. The SGZ and 
SVZ both contain the neurotransmitters GLU and DA56. Binge METH-induced neurodegeneration takes 
at least 3 days3; therefore, the changes in LINE-1 expression were not related to METH withdrawal. It 
remains to be determined whether the observed changes promote METH neurotoxicity, which is a likely 
scenario because a transient increase in LINE-1 expression, particularly in ORF-2, is cytotoxic57,58.
High doses of METH induce DNA breaks8,59 and apoptotic and necrotic death of SGZ and SVZ 
cells9,46,60. LINE-1 can “jump” into DNA at strand breaks61. Consequently, an increased copy number 
of ORF-1 gDNA at 7 days might reflect LINE-1 integration into METH-damaged DNA. However, the 
majority of LINE-1 insertions are 5′ –truncated and only 1 kbp in length37, suggesting that new LINE-1 
insertions rarely contain ORF-1. In view of this fact, the increases in ORF-1 gDNA might reflect 
increased proliferation and/or survival of cells in neurogenic zones. Another potential interpretation of 
the observed results is that LINE-1 expression is induced without subsequent retrotransposition of the 
element, with the observed increases in ORF-1 gDNA being due to chromosome duplication, aneuploidy, 
or copy number variation34. The METH-induced increase in ORF-1 copy numbers within gDNA in the 
liver likely reflects neurotoxic effects of the drug on this tissue. METH induces oxidative damage to 
proteins, lipids and DNA, impairs mitochondria and reduces GSH supplies in the rodent liver to a sim-
ilar extent to that in the rodent brain62. By contrast, there is no evidence for METH toxicity in animal 
or human muscle tissue (with the exception of the heart). In agreement with these data, there was no 
difference in the ORF-1 copy numbers in the muscle tissue of METH-exposed rats and saline controls. 
In summary, the observed increases in the ORF-1 gDNA levels in the dentate gyrus, as well as in the 
striatum and liver, very likely represent toxic METH-induced epigenetic events.
The decreases in ORF-1 mRNA levels observed in the dentate gyrus and striatum at 7 days after 
METH may reflect adaptive downregulation of LINE-1 transcription, ORF-1-containing cell loss within 
the neurogenic niches, decreased proliferation of these cells, and/or decreased survival of new neurons. 
Any of these events is plausible because high-dose METH decreases cell proliferation, differentiation, 
and survival, and induces the death of stem and progenitor cells in the SGZ and SVZ60,63. Alternatively, 
the decrease in ORF-1 mRNA might reflect, in part, the incorporation of LINE-1 into the genome with-
out further ORF-1 mRNA production. The last scenario is supported by the positive correlation of the 
ORF-1 mRNA levels with the ORF-1 gDNA levels in the dentate gyrus; however, this result must be 
confirmed with larger group sizes.
The LINE-1 promoter region is strongly methylated at most CpG sites in the brain37,64. The methyl-
ation status of the LINE-1 promoter determines, in part, rat LINE-1 transcription31,38. We found only a 
small decrease (− 1%) in the methylation levels of the LINE-1 promoter in the dentate gyrus, which was 
mainly due to the de-methylation of CpG9 and CpG3 sites. In the striatum, LINE-1 promoter hypometh-
ylation, if it occurred, might have been diluted out, as the LINE-1 activation occured mainly in the SVZ. 
The required minimum degree of hypomethylation for LINE-1 gene activation is unknown. It is possible 
that, in our study, LINE-1 activation in the dentate gyrus was triggered by low-level de-methylation at 
the third and ninth individual CpG sites. This scenario is supported by the finding that the induction of 
LINE-1 transcription is dependent on the position rather than the number of hypomethylated CpGs31. 
In HeLa cells, methylation at the first seven CpGs in the LINE-1 promoter has been shown to be essen-
tial for LINE-1 inhibition31. The lack of correlation between the ORF-1 mRNA levels and the LINE-1 
promoter methylation levels does not support this hypothesis. Our results together with the finding 
that morphine-increased LINE-1 expression does not correlate with LINE-1 hypomethylation40, point 
to mechanisms independent of cytosine methylation at the LINE-1 promoter CpG sites. The mecha-
nism of transcriptional activation of repetitive elements has not been definitively elucidated; therefore, 
other factors may be involved in LINE-1 activation, such as SOX2, chromatin structure, DNA-editing 
proteins, the canonical WNT pathway, RNA helicases, small interfering RNAs34,65, small piRNAs66 and 
P1-LINE-1 RNA67, and HDACs32. Of these factors, HDACs are strong candidates for LINE-1 regulation 
after METH exposure28. In addition, the oxidation of methylated cytosines68, the hypomethylation of 
CpG sites other than the assessed CpG sites within the LINE-1 promoter region, or the methylation 
level of CpG sites outside the LINE-1 promoter region may also have played a part in activating of 
this element69. We focused on the LINE-1 promoter region only and did not distinguish between DNA 
methylation forms. Of note, LINE-1 sequences that are located within the LINE-1 promoter region do 
not share homology between species.
Both toxic and nontoxic regimens of METH alter the gene expression in striatal and hippocampal 
neurons7,21,70–72. Consequently, nontoxic METH doses might have effects on brain LINE-1 that are similar 
to those of neurotoxic METH doses. The METH-induced changes in gene expression are accompanied by 
changes in histone acetylation and deficits in certain HDACs21,28. On the other hand, histone acetylation 
and deficits in HDACs cause increased LINE-1 activity32, suggesting that METH-induced decreases in 
certain HDACs activate LINE-1, which in turn participates in the regulation of gene expression. The in 
vivo experiments did not determine whether neurotoxic METH doses induce LINE-1 retrotransposition 
and whether LINE-1 activity mediates METH neurotoxicity. If METH-mediated LINE-1 activation is 
followed by its retrotransposition in vivo, it might initiate a vicious cycle of neurotoxicity via DNA 
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breakage57,61. Even in the absence of LINE-1 retrotransposition, LINE-1 might still participate in mediat-
ing of METH’s toxic effects in vivo via increased ORF-1 and ORF-2 expression because there is evidence 
of a physiological role of LINE-1 expression in responses to stress73,74 and in brain plasticity33,37. Altered 
levels of LINE-1 expression can trigger neurological impairments34, suggesting that LINE-1 induction 
may contribute to the development of cognitive impairments in human METH users.
Methods
Animals. Adult male Sprague-Dawley rats (Harlan, Indianapolis, IN, USA) (weighing 250–300 g 
on arrival) were pair-housed under a 12 h light/dark cycle in a temperature-controlled (20–22 °C) and 
humidity-controlled room. Food and water were available ad libitum. The animals were allowed to 
acclimatize for one week before the start of the study. All animal procedures were conducted between 
7:00 A.M. and 7:00 P.M. in strict accordance with the National Institutes of Health (NIH) Guide for 
the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee (IACUC) at Wayne State University (animal protocol #A 05-07-13). The description of ani-
mal procedures meets the ARRIVE recommended guidelines described by The National Centre for the 
Replacement, Refinement and Reduction of Animals in Research75.
Administration of methamphetamine. (+ )-Methamphetamine hydrochloride (METH, 10 mg/kg) 
(Sigma-Aldrich, St. Louis, MO) or saline (1 mL/kg) was administered to the rats every 2 h in four succes-
sive intraperitoneal (i.p.) injections. METH neurotoxicity is associated with hyperthermia, which peaks 
at approximately 1 h after each injection. Therefore, the core body temperatures of the rats were measured 
with a rectal probe digital thermometer (Thermalert TH-8; Physitemp Instruments, Clifton, NJ) before 
the beginning of the treatment (baseline temperatures) and at 1 h after each METH or saline injection. 
Rats were sacrificed by decapitation at 1 h (used for LINE-1 methylation analysis), 24 h or 7 days (used 
for multiple analysis) after the last injection of the drug or saline.
Tissue collection. The brains were removed, dissected out into discrete brain areas (striatum, dentate 
gyrus, Ammon’s horn, prefrontal cortex, and cerebellum) and stored at − 80 °C until assayed. The SVZ 
was dissected out together with the striatum whereas the SGZ was dissected out together with the den-
tate gyrus. The dentate gyrus was dissected out according to a previously described protocol76 modified 
for the rat brain. Briefly, the brain was cut sagittally to divide the hemispheres, which were then placed 
medial side up after removal of the regions posterior to lambda. The dentate gyrus and Ammon’s horn 
(CA1 and CA3) (which were visible upon removal of thalamus and hypothalamus) were dissected out 
using fine tip surgical instruments. Liver and muscle tissues were also collected and stored at –80°C 
until analysis.
Real-time polymerase chain reaction and pyrosequencing. The levels of ORF-1 mRNA and 
ORF-1 gDNA in the dissected brain areas from METH-and saline-treated rats were determined using 
real-time quantitative polymerase chain reaction PCR (qPCR). DNA methylation of the first ten CpG 
sites within the LINE-1 promoter region was determined by pyrosequencing. GADPH was used as a ref-
erence gene in all analyses. The analyses were conducted at EpigenDx Inc. (Hopkinton, MA). DNA and 
RNA were extracted from two separated pieces of tissue. A 250 ng of total RNA from each tissue sample 
was used for cDNA synthesis with High Capacity cDNA Reverse Transcription kit (Life Technologies, 
Carlsbad, CA). The DNA and cDNA quantification was conducted by qPCR using primers comple-
mented to sequences in LINE-1 ORF-1 region. The mRNA and gDNA copy numbers were calculated 
from the standard curves. For DNA methylation analysis, 500 ng of DNA from each rat brain tissue sam-
ple was first treated with bisulfite and subsequently purified using Zymo Research DNA columns (Zymo 
Research, Irvine, CA). A 1/20th of eluted solution was used for each PCR. Biotinylated PCR products 
were bound to Streptavidin Sepharose HP (GE Healthcare, Waukesha, WI). Immobilized PCR products 
were purified using Pyrosequencing Vacuum Prep Tool (Qiagen, Valencia, CA) according to the manu-
facturer’s instructions. The 0.2 μ M pyrosequencing primer was annealed to purified single-strained PCR 
product. The PCR products (10 uL) were sequenced using Pyrosequencing PSQ96 HS System (Biotage 
AB, Charlotte, NC). The methylation status of each locus was analyzed individually as a T/C SNP using 
QCpG software (Pyrosequencing, Qiagen). The data is expressed as LINE-1/GADPH ratios normalized 
to saline controls (mean ± SEM).
Immunohistochemistry. Brain tissue from the rats sacrificed by decapitation at 24 h after the last 
injection of METH or saline was fixed in 4% paraformaldehyde for 24 h then incubated in 20% and 30% 
buffered glycerol concentrations for 24 h each (4 °C). Every other of the coronal sections (20 μ m, 3–4/
rat) from the SVZ (1.18–0.26 from Bregma) and the dentate gyrus (− 3.12 to –4.68 from Bregma) were 
examined using immunofluorescence. Sections were pretreated with 1× citrate buffer for 40 min at 70 °C 
then allowed to cool to room temperature before being blocked in a blocking buffer (phosphate-buffered 
saline (PBS), 0.1% Triton X-100, and 5% bovine serum albumin (BSA)) for 1 h at room tempera-
ture. The sections were then incubated overnight at 4 °C with a chicken anti-ORF-2 (1:200, Rockland 
Immunochemicals Inc., Limerick, PA1) and a rabbit anti-doublecortin (1:100, Abcam, Cambridge, MA) 
primary antibodies. The next day, the sections were incubated for 3 h at room temperature with the 
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corresponding secondary antibodies, anti-chicken Alexa-488 (1:1000) and anti-rabbit Alexa-594 (1:2000) 
(Life Technologies, Carlsbad, CA). The incubations with primary and secondary antibodies were separated 
by three 5 min-long washes with PBS that contained 0.1% Triton and 5% BSA. The nuclei were labeled 
with DRAQ5 dye (Life Technologies). The sections were mounted on slides using Flouromount mount-
ing medium (Sigma-Adlrich). Images were captured using Leica TCS SPE-II confocal microscope under 
the 63× oil objective (Leica). The ORF-2 immunofluorescence was measured in four non-overlapping 
areas per slice and averaged. Mean of the averages was then calculated for each rat.
Cell culture, cell transfection and drug treatments. PC12 cells (a rat adrenal gland pheochro-
mocytoma cell line) and PA-1 cells (an ovarian teratocarcinoma cell line) (ATCC, Manassas, VA) were 
grown in Gibco RPMI-1640 medium (Life Technologies) containing 10% horse serum and 5% fetal 
bovine serum (FBS). The plasmids p99-LRE3-eGFP and JM111-eGFP (kindly gifted by Dr. Alysson 
Muotri, US San Diego, CA, US) were used for the transient transfection of PC12 and PA-1 cells and 
served as the LINE-1 retrotransposition indicator and negative control, respectively. The cells were grown 
to an approximately 80% confluence. Plasmid DNA (1.2 μ g) was mixed with 2 μ L Lipofectamine 2000 
(Life Technologies) and added to the cells according to the manufacturer’s instructions. The cells were 
trypsinized two days after the transfection, re-seeded into a 6-well plate, and treated with 150 or 300 μ M 
METH for 10–14 days. Puromycin (7.5 μ g/mL) was added to the cells on the 1st day of METH treatment. 
The cells were grown until the appearance of an eGFP fluorescence signal (10–14 days), which indicates 
LINE-1 retrotransposition36. The eGFP signal was recorded using the EVOS FL Cell Imaging System 
(Life Technologies). A reverse transcriptase inhibitor, azidothymidine (AZT, 20 μ M, Sigma-Aldrich), was 
added to some wells to ascertain that the eGFP signal was the result of LINE-1 retrotransposition. The 
transfection efficiency of the cells was assessed using the positive control plasmid pCMV6-AC-GFP 
(OriGene, Inc., Rockville, MD) and was estimated to be 70–80%. Each experiment was conducted three 
times. To monitor ORF-2 expression, LRE3-eGFP-transfected PC12 cells were puromycin-selected, 
untreated or treated with 2 mM DA or 2 mM GLU and evaluated for viability on an hourly basis using 
propidium iodide. JM111-eGFP-tranfected cells served as controls. After 4 h, the cells were fixed in 4% 
paraformaldehyde and permeabilized with 0.1% Triton X-100 for 10 min. After 1 h blocking step with 5% 
BSA, the cells were incubated (overnight, 4 °C) with an anti-ORF-2 primary antibody (1:1000, Rockland 
Immunochemicals Inc., Limerick, PA), the corresponding anti-chicken Alexa-488 secondary antibody 
(1:400, 1 h at RT), and DAPI to visualize the nuclei. Images were recorded using EVOS FL microscope.
Statistical analysis. The comparisons made in the study were pre-planned comparisons. We estab-
lished a priori the SGZ and SVZ as potentially affected brain regions in METH-exposed rats and chose 
other samples based on existing knowledge regarding the METH and LINE-1 effects on the brain, liver 
and muscle. Differences between the control and METH groups were analyzed by the Student’s t-test 
and were followed by the Bonferroni correction (which adjusts for the probability of Type I errors in 
multiple comparisons). A two-way repeated-measures ANOVA followed by the Student-Newman-Keuls 
post hoc test was performed on the temperature data. Correlations between indices were determined 
using Pearson’s analysis. To avoid Type II errors (failures to reject a false null hypothesis), some data were 
grouped before analysis or are presented in two ways: (1) adjusted for Type I errors and (2) unadjusted. 
The results are expressed as the mean ± SEM. Significance was set at p < 0.05.
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